tolerance
发表于 2025-3-23 12:19:22
http://reply.papertrans.cn/47/4693/469201/469201_11.png
inchoate
发表于 2025-3-23 15:43:58
IP Issues of Therapeutic Antibodies,he broadest scope of protection, other ways of follow-up protection should be considered by innovators to achieve as long protection as possible. Further, in case a theoretical antibody against a given target is already prior art, innovators should be aware of methods to create compound protection f
orient
发表于 2025-3-23 20:06:17
http://reply.papertrans.cn/47/4693/469201/469201_13.png
nettle
发表于 2025-3-23 22:45:55
http://reply.papertrans.cn/47/4693/469201/469201_14.png
deactivate
发表于 2025-3-24 06:07:28
2192-9904 rts?.Includes supplementary material: .SpringerBriefs in Biotech Patents present timely reports of intellectual properties (IP) issues and patent aspects in the field of biotechnology. This new volume in the series focuses on the particular IP issues of therapeutics, vaccines and molecular diagnosti
懒洋洋
发表于 2025-3-24 08:47:42
http://reply.papertrans.cn/47/4693/469201/469201_16.png
控制
发表于 2025-3-24 11:40:11
Book 2012 technologies and compounds used therein. The third chapter gives a broad overview of areas of law that are particularly relevant to the patenting of peptide vaccines and therapeutic peptides as products and in compositions. The scope of patentable subject matter is discussed, as it has been the focus of much wrangling and debate in the courts..
GLOOM
发表于 2025-3-24 15:23:23
http://reply.papertrans.cn/47/4693/469201/469201_18.png
gimmick
发表于 2025-3-24 21:38:12
http://reply.papertrans.cn/47/4693/469201/469201_19.png
一骂死割除
发表于 2025-3-25 00:42:56
SpringerBriefs in Biotech Patentshttp://image.papertrans.cn/i/image/469201.jpg